desloratadine
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
80
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Conjunctivitis, Allergic
Conditions
Conjunctivitis, Allergic
Trial Timeline
Mar 1, 2005 โ May 28, 2005
NCT ID
NCT00311844About desloratadine
desloratadine is a approved stage product being developed by Organon for Conjunctivitis, Allergic. The current trial status is completed. This product is registered under clinical trial identifier NCT00311844. Target conditions include Conjunctivitis, Allergic.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00723736 | Pre-clinical | Completed |
| NCT00724698 | Pre-clinical | Completed |
| NCT00311844 | Approved | Completed |
| NCT00795522 | Approved | Completed |
| NCT00805324 | Phase 3 | Completed |
| NCT00805584 | Approved | Completed |
| NCT00817076 | Phase 3 | Completed |
| NCT00795158 | Phase 3 | Completed |
Competing Products
20 competing products in Conjunctivitis, Allergic
Other Products from Organon
tibolone + raloxifenApproved
80
ezetimibe + statinsApproved
80
losartan potassium + Comparator: carvedilol + Comparator: losartan (+) hydrochlorothiazide (HCTZ) + Comparator: carvedilol (+) hydrochlorothiazideApproved
80
Desloratadine 5 mg + fexofenadineApproved
80
simvastatin (+) ezetimibe + atorvastatinApproved
80